Abstract：
The course of COVID-19 with an incidence of 15-42% can be complicated by the development of acute respiratory distress syndrome (ARDS). The mortality rate with severe forms exceeds 60%, which sometimes requires extracorporeal methods of life support.
OBJECTIVE: The aim of this study was to analyse the therapeutic efficacy of V-V ECMO in patients with ARDS caused by SARS-CoV-2.
METHODS: A retrospective analysis was performed in patients with acute lung injury caused by COVID-19 and treated with V-V ECMO within a period from February 2020 to May 2021 at the ECMO Center of the Heart Institute Ministry of Health of Ukraine. All patients had PCR testing for viral RNA particles using RT-PCR ELITe analyser.
RESULTS: During this period, 7 cases reported of V-V ECMO for ARDS caused by COVID-19. Five of seven patients were urgently transferred to our ECMO Center from other medical institutions, while 2 patients were transferred to the hospital being already connected to ECMO, and one patient was connected to ECMO immediately after hospitalization. The most common ECMO complication was circuit thrombosis - 42.9% (3/7), which required oxygenator replacement - in 2 cases and circuit replacement - in 1 case. Three patients had bleeding at the cannulation site. ECMO mortality rate was 57.1% (4/ 7), while the 30-day mortality rate - 71.4% (5/7).
CONCLUSIONS: In our case series, out of seven critically ill COVID-19 patients who required ECMO to maintain adequate oxygenation, inpatient mortality was observed in 71.4%.
OBJECTIVE: The aim of this study was to analyse the therapeutic efficacy of V-V ECMO in patients with ARDS caused by SARS-CoV-2.
METHODS: A retrospective analysis was performed in patients with acute lung injury caused by COVID-19 and treated with V-V ECMO within a period from February 2020 to May 2021 at the ECMO Center of the Heart Institute Ministry of Health of Ukraine. All patients had PCR testing for viral RNA particles using RT-PCR ELITe analyser.
RESULTS: During this period, 7 cases reported of V-V ECMO for ARDS caused by COVID-19. Five of seven patients were urgently transferred to our ECMO Center from other medical institutions, while 2 patients were transferred to the hospital being already connected to ECMO, and one patient was connected to ECMO immediately after hospitalization. The most common ECMO complication was circuit thrombosis - 42.9% (3/7), which required oxygenator replacement - in 2 cases and circuit replacement - in 1 case. Three patients had bleeding at the cannulation site. ECMO mortality rate was 57.1% (4/ 7), while the 30-day mortality rate - 71.4% (5/7).
CONCLUSIONS: In our case series, out of seven critically ill COVID-19 patients who required ECMO to maintain adequate oxygenation, inpatient mortality was observed in 71.4%.
摘要：
发病率为15-42%的COVID-19的病程可能因急性呼吸窘迫综合征（ARDS）的发展而复杂化。严重形式的死亡率超过60％，这有时需要体外的生命支持方法。
目的：本研究的目的是分析V-VECMO对SARS-CoV-2引起的ARDS患者的治疗效果。
方法：对2020年2月至2021年5月期间在乌克兰卫生部心脏研究所ECMO中心接受V-VECMO治疗的COVID-19急性肺损伤患者进行了回顾性分析。所有患者使用RT-PCRELITe分析仪对病毒RNA颗粒进行PCR检测。
结果：在此期间，报告V-VECMO治疗COVID-19所致ARDS7例。7名病人中有5名已从其他医疗机构紧急转送至我们的ECMO中心,当两名患者被转移到医院时，他们已经连接到ECMO，1例患者在住院后立即接受了ECMO治疗.最常见的ECMO并发症是回路血栓形成-42.9％（3/7），需要更换充氧器-2例和电路更换-1例。三名患者在插管部位出血。ECMO死亡率为57.1%(4/7),而30天死亡率-71.4%(5/7)。
结论：在我们的案例系列中，在7名需要ECMO维持足够氧合的重症COVID-19患者中，住院死亡率为71.4%.
目的：本研究的目的是分析V-VECMO对SARS-CoV-2引起的ARDS患者的治疗效果。
方法：对2020年2月至2021年5月期间在乌克兰卫生部心脏研究所ECMO中心接受V-VECMO治疗的COVID-19急性肺损伤患者进行了回顾性分析。所有患者使用RT-PCRELITe分析仪对病毒RNA颗粒进行PCR检测。
结果：在此期间，报告V-VECMO治疗COVID-19所致ARDS7例。7名病人中有5名已从其他医疗机构紧急转送至我们的ECMO中心,当两名患者被转移到医院时，他们已经连接到ECMO，1例患者在住院后立即接受了ECMO治疗.最常见的ECMO并发症是回路血栓形成-42.9％（3/7），需要更换充氧器-2例和电路更换-1例。三名患者在插管部位出血。ECMO死亡率为57.1%(4/7),而30天死亡率-71.4%(5/7)。
结论：在我们的案例系列中，在7名需要ECMO维持足够氧合的重症COVID-19患者中，住院死亡率为71.4%.
